BPC-157 + TB-500 — the soft-tissue recovery stack
The common healing stack pairs BPC-157 with TB-500 — two peptides that support tissue repair through complementary routes. An FDA advisory committee recommended both in July 2026, and since October HHS tolerates compounding each one on its own, but not the two mixed in one vial.
Both halves are available from the same provider
BPC-157 and TB-500 are the most common pairing in peptide-based recovery, and the reason is that they support tissue repair from two different directions. BPC-157 is a 15-amino-acid peptide based on a sequence found in gastric juice; in the lab its signature action is driving angiogenesis — the body forming new blood vessels — through the VEGFR2–Akt–eNOS pathway, alongside repair-related growth factors. TB-500 is a short fragment of thymosin beta-4 that works on actin regulation, which moves repair cells toward damaged tissue, plus angiogenesis and a calming of inflammatory signaling.
Put simply, BPC-157 leans local and vascular (and uniquely supports the gut), while TB-500 acts more systemically on cell migration and flexibility. In principle they cover different steps of the same repair cascade.
“The pairing logic is sound on paper — two mechanisms, one repair process — but ‘on paper’ is exactly where the combination’s evidence still lives.”
That’s the honest catch. The encouraging data for both peptides is overwhelmingly preclinical — cells and rodents — and there’s no published human trial of the combination for any outcome. BPC-157 has a Phase II trial for acute hamstring strain that only began in 2026; TB-500’s human data is mostly on its parent protein, not the fragment itself. For the full mechanisms and trial history on each, read the deep-dives on PeptideWellness.
Who it's for (or who should avoid)
What it's aimed at
This stack is most commonly reached for by:
- People recovering from soft-tissue injury — tendon, ligament, or muscle strains that are slow to settle
- Post-surgical or overuse recovery — where the goal is supporting the repair process alongside structured rehab
- Athletes managing training load — though with a major caveat below
- Gut-related goals — where BPC-157 specifically is the driver
Who should avoid it
- Anyone with an active or recent cancer — both peptides promote new blood-vessel growth, which is the last thing you want near a tumor, so oncology input comes first
- Anyone pregnant, breastfeeding, or planning a pregnancy — no controlled human data
- Competitive athletes — TB-500 and thymosin beta-4 are on the WADA Prohibited List (class S2); a positive test is a real risk
- Anyone relying on gray-market “research use only” product — quality and identity are frequently untested, which is a safety issue on its own
Dose, timing and cycling
Because none of this is FDA-approved for these uses, there’s no established clinical dose — only patterns reported by users and clinics, offered here as context, not a recommendation.
The reported shape is a time-limited course with the two run concurrently so their mechanisms overlap:
TB-500 is usually described in two phases — a higher starting phase, then lower maintenance — while BPC-157 is dosed daily, which follows from its short half-life (under 30 minutes in animals)
BPC-157 is used both as a subcutaneous injection, often placed near the target when it’s a specific tendon or joint, and orally when the gut is the target; TB-500 is injected subcutaneously and acts more systemically
both come as a freeze-dried powder reconstituted with bacteriostatic water
One access note worth flagging: neither peptide is on the 503A list that would authorize compounding. Since October 28, 2026, HHS has said it will not act against pharmacies that compound each one separately under set conditions, but a single vial containing both is outside that policy. Dose, route, and duration are decisions for a licensed prescriber — not something to reverse-engineer from a forum.
No measured timeline
No trial has tested BPC-157 and TB-500 together, and none has measured how soon either works in people, so we do not draw a week-by-week picture. Agree with your prescriber what you will measure and when you will stop.
Both halves are available from the same provider
A stack is something a clinician decides to run, not a product on a shelf. Some sellers compound pairs like this into one vial, but that vial is still a prescription, written after an intake, not something to add to a basket. So this is the per-half answer — who sells each one today, and what to do about a half nobody sells.
BPC-157
- Defy Medical Tampa clinic, physician-led
- RxPepsDirect Per-vial prices, 503A pharmacy in Texas
- Live Vital Physician-led, monthly pricing, Draper UT
- PeRx Peptide-only telehealth, Wellness MD Group PC
TB-500
- Defy Medical Tampa clinic, physician-led
- RxPepsDirect Per-vial prices, 503A pharmacy in Texas
- Live Vital Physician-led, monthly pricing, Draper UT
- PeRx Peptide-only telehealth, Wellness MD Group PC
Will it work where you live?
Most sellers claim all fifty states or publish nothing about coverage; a few name the states they serve or exclude, and each provider page says which. Either way it is the seller's own claim, so we can't filter a list by state without inventing a fact. What we can tell you is which state-level rules decide access: telehealth rules, non-resident pharmacy licensing, and who is allowed to prescribe.
Find who prescribes this pair
The licensed providers that sell BPC-157 or TB-500, what each charges to start, and what they publish about your state. No signup.
Questions we get about BPC-157 + TB-500
Is the BPC-157 + TB-500 stack FDA-approved?
No — and there's no approved combination product. Neither peptide has ever been an FDA-approved drug. Both were in the FDA's interim 503A category 2 until April 2026, when their nominations were withdrawn. In July 2026 the agency's Pharmacy Compounding Advisory Committee recommended adding both to the 503A bulks list, BPC-157 for ulcerative colitis and TB-500 for wound healing; the FDA has not acted. Since October 28, 2026, HHS has said it will not act against licensed pharmacies that compound each peptide on its own for a named patient; a combined vial is outside that policy, because it requires a single active ingredient.
Is it legal?
Each peptide on its own, under conditions; the premixed pair, no. Neither is on any list that authorises compounding: section 503A lets a pharmacy compound only from an ingredient of an FDA-approved drug, a substance with a USP monograph or one on the FDA's 503A bulks list. On October 28, 2026, HHS said it will not take action against State-licensed pharmacies and licensed physicians that compound BPC-157 or TB-500 for a named patient while the FDA decides whether to list them, if each product contains only one active ingredient, uses a covered route (BPC-157 by injection, by mouth or on the skin; TB-500 by injection only), comes from an FDA-registered manufacturer named on a certificate of analysis, and serious side effects are reported to the FDA. A vial with both peptides in it fails the single-ingredient condition. HHS can withdraw the policy. Buying either from "research chemical" sources is not a lawful supply route, and the quality is untested.
Does the combination work better than one peptide alone?
The mechanistic rationale is reasonable — BPC-157 leans local and vascular, TB-500 more systemic on cell migration. But no published human trial has tested the combination for any outcome, and none has compared the pair to either peptide alone. "Better together" is a hypothesis, not a demonstrated result.
Are there side effects?
Short-term reports are mostly injection-site irritation, but long-term human safety is uncharacterized for both. Because both promote new blood-vessel growth, anyone with an active or recent cancer should involve an oncologist first. Both are inappropriate in pregnancy and breastfeeding, and TB-500 is banned in tested sport (WADA class S2).
How much does it cost?
There's no standard price. On the sellers' own pages on 14 October 2026, RxPepsDirect listed one combined BPC-157/TB-500 vial (15mg + 15mg) at $100, plus a $39 visit per order; other sellers quote the pair inside an intake or as a monthly protocol. A vial is a quantity, not a month, and how long it lasts depends on the dose prescribed. These aren't approved medications, insurance doesn't cover compounded drugs, and the FDA has not acted on its advisory committee's July 2026 recommendation, so any figure can move.
We publish no medical reviewer by design. Every claim on this page traces to a source we hold on file, and the reviewed write-up with those citations lives on our hub — one per peptide, because the pair itself has no single write-up.
Other pairings, and the peptides around them
The latest peptide research and reviews, in your inbox
We are preparing a newsletter: independent updates on peptide therapy, news from compounding pharmacies, and guides. Leave your email and we will send the first issue as soon as it launches.
